The National Institute on Aging (NIA) awarded a $490,262 Project Grant (CFDA 93.866 - Aging Research) to Plans4Care Inc. on June 15, 2025 to develop and test a digital platform called "Activities4Care". The platform aims to provide customized, evidence-based activity plans for caregivers of people living with Alzheimer's disease and related dementias. The key products to be delivered under this Fast-Track SBIR award include: A clickable prototype of the Activities4Care platform that...
This Project Grant award of $353,391.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to validate the use of a "Personal Learning Curve" paradigm as a sensitive marker of early memory decline related to Alzheimer's disease (AD) biomarkers in a large, diverse sample of older adults. The study seeks to determine if this digital cognitive assessment tool, which measures learning over repeated evaluations, can detect subtle AD-related memory failures...
The Project Grant award R01AG087243, totaling $3,374,303 and awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), will fund the "Understanding Ambulatory Care Utilization in Alzheimer's Disease and Related Dementias (ACUA)" project. This project aims to investigate the role of fragmented ambulatory care in the diagnosis and management of people living with dementia. The key products and services to be delivered include: Secondary analyses of two NIA-funded...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $811,228 to B.A. Maze, Inc. to develop the At-Home Health Station (AHS), a plug-and-play modular system designed to simplify digital health experiences for individuals with cognitive impairment or Alzheimer's disease and related dementias (CI/ADRD). The AHS system aims to promote health function and independence through remote patient monitoring, while also providing caregivers a platform for...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...
This Project Grant award from the National Institute on Aging (Aging Research, CFDA 93.866) supports a $7,997,945 initiative to improve the diagnosis of Alzheimer's disease and related dementias in primary care settings. The project, led by the University of California, San Francisco, aims to demonstrate that a comprehensive diagnostic toolkit, combined with expert-led case conferences, can help primary care providers accurately distinguish mild cognitive impairment and Alzheimer's-related...
This $1,230,000 Project Grant awarded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support the development and deployment of closed-loop digital interventions through a remote clinical trials platform. The overarching goal is to leverage technology to facilitate memory and cognitive function and prevent or delay age-related cognitive decline, particularly in older adults at risk of Alzheimer's disease and related dementias. The...
The National Institute on Aging (NIA) awarded a $499,996 Project Grant under the Aging Research federal grant program (CFDA 93.866) to Beaver Health, Inc., a minority-owned, woman-owned small business, to develop a prototype of the COMPASS conversational AI assistant. COMPASS is designed to provide personalized, culturally responsive support and coordination for Alzheimer's disease and related dementia (ADRD) caregivers in real-time. The 12-month project aims to develop and test the initial...
This $334,788 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the impact of recent revisions to the Medicare home health payment system (Patient-Driven Groupings Model or PDGM) on access, care delivery, and outcomes for community-living Medicare beneficiaries with Alzheimer's disease and related dementias (ADRD). The 2-year study, starting September 1, 2023, will leverage Medicare claims, home health assessment, and agency data to:...
This Project Grant award of $2,683,965 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support the development and optimization of an improved all-human cellular system, or "brain-chip", for studying Alzheimer's disease and related dementias (ADRDs). The key objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into...
A NOVEL PLATFORM TO FACILITATE PROVIDER ADOPTION OF COGNITIVE CARE PLANNING - SUMMARY ALZHEIMER'S DISEASE AND ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (AD/ADRD) ARE PROGRESSIVE DISEASES IN WHICH PATIENTS' PHYSICAL AND COGNITIVE ABILITIES DECLINE PRECIPITOUSLY OVER TIME. ALTHOUGH THERE IS CURRENTLY NO CURE AND VERY FEW PHARMACEUTICAL-BASED TREATMENT OPTIONS, SOME INTERVENTIONS CAN HELP IMPROVE PATIENT HEALTH AND QUALITY OF LIFE. COGNITIVE CARE PLANNING (CCP) REFERS TO THE PRACTICE OF SYSTEMATICALLY COMPILING AND COMMUNICATING PERSONALIZED RECOMMENDATIONS AND DIRECTIONS FOR FOLLOW-UP CARE TO AD/ADRD PATIENTS. THIS ACTIVITY CAN LEAD TO BETTER CARE MANAGEMENT, THUS BENEFITING THE HEALTH AND WELL-BEING OF BOTH PATIENTS AND THEIR CAREGIVERS. DESPITE THIS, CCP IS SCARCELY SEEN IN ROUTINE CARE AND SEVERAL BARRIERS ATTRIBUTE TO THE SLOW ADOPTION RATE. FIRST, CCP IS TIME CONSUMING DUE TO THE SIZABLE AMOUNT OF CONTENT TO ASSEMBLE; COGNITIVE ASSESSMENT DATA, EMOTIONAL HEALTH STATUS, AND CAREGIVER KNOWLEDGE, TO NAME A FEW. SECOND, THE EXPERTISE REQUIRED TO INTERPRET PATIENT INFORMATION AND GENERATE INDIVIDUALIZED RECOMMENDATIONS FOR CARE CAN BE DAUNTING TO NON-SPECIALISTS; WHEREAS DUE TO A SHORTAGE OF DEMENTIA SPECIALISTS, THE BURDEN OF CARE FOR THIS PATIENT POPULATION MOST OFTEN FALLS TO NON-SPECIALIST PRIMARY CARE PHYSICIANS (PCPS). THE CONSIDERABLE TIME INVESTED INTO DEVELOPING A CARE PLAN RESULTS IN A FINANCIAL BARRIER AS WELL. IN 2018 A NEW BILLING CODE WAS ESTABLISHED TO ADDRESS THIS BUT REIMBURSEMENTS RATES REMAIN LOW. BRAINCHECK HAS AN OVERARCHING GOAL TO ENHANCE THE ADOPTION OF FORMAL CCP AS PART OF ROUTINE CARE FOR AD/ADRD PATIENTS. WE HAVE DEVELOPED AN APP-BASED TOOL THAT INTEGRATES ASSESSMENT SCORES, PROVIDER INPUT, AND PATIENT/CAREGIVER REPORTED DATA TO GENERATE AN INDIVIDUALIZED, EASY-TO-READ DOCUMENT TO BE DELIVERED DURING A CLINIC VISIT. A PROTOTYPE OF THIS TOOL, BC-CARE, WAS POSITIVELY RECEIVED BY AN INITIAL GROUP OF SPECIALIST AND NON-SPECIALIST USERS AND THEIR FEEDBACK WAS USED TO ITERATE ON KEY FEATURES AND USER INTERFACE DESIGN. MOREOVER, CLINICAL PRACTICES REPORTED GREATER SUCCESS IN CLAIMING MEDICARE REIMBURSEMENT AFTER USING BC-CARE. BASED ON THIS PRELIMINARY WORK, WE BELIEVE BC-CARE MAKES CARE PLANNING FASTER, MORE ACCESSIBLE, AND MORE LIKELY TO BE REIMBURSED. HERE, WE PROPOSE PHASE II STUDIES TO SYSTEMATICALLY VALIDATE THE IMPACT OF BC-CARE ON THE ADOPTION OF CCP. SPECIFICALLY, WE WILL: MEASURE THE TIME SPENT ON CARE PLANNING, CARE PLAN COMPLETION RATE, AND REIMBURSEMENT SUCCESS RATE FOR PROVIDERS USING BC-CARE (AIM 1); COMPARE THE EXTENT TO WHICH PROVIDERS ADOPT CARE PLANNING BEFORE AND AFTER GAINING ACCESS TO THE BC-CARE TOOL (AIM 2); AND TRACK SPECIFIC IMPACTS ON HEALTH AND WELL-BEING AMONG PATIENTS AND CAREGIVERS WHO RECEIVED A CARE PLAN VIA BC-CARE COMPARED TO THOSE RECEIVING CARE-AS-USUAL (AIM 3). BY ADDRESSING THREE OF THE MAJOR BARRIERS PREVENTING PROVIDERS FROM OFFERING CARE PLANNING SERVICES TO THEIR PATIENTS WITH AD/ADRD, WE PREDICT OUR TECHNOLOGICAL SOLUTION WILL SUBSTANTIALLY ENHANCE ADOPTION, THUS OFFERING A REALISTIC PATH TOWARD IMPROVING HEALTH AND WELL-BEING BY IMPROVING THE APPROACH TO ROUTINE COGNITIVE CARE.